BMS-737

• Description :

  BMS-737 (compound 33) is a non-steroidal, reversible small molecule inhibitor. BMS-737 exhibits 11-fold selectivity for CYP17 lyase over CYP17 hydroxylase. BMS-737 is designed to inhibit castration-resistant prostate cancer (CRPC) and significantly reduces testosterone levels without significant effects on orrodermal hormone and glucocorticoid levels[1].

• CAS Number :

  [1356053-63-8]

• UNSPSC :

  12352005

• Target :

  Cytochrome P450

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/bms-737.html

• Smiles :

  FC1=CC=C(N2N=CC3=C(C4=C(N)N=CN=C4)C=CN=C32)C=C1

• Molecular Formula :

  C16H11FN6

• Molecular Weight :

  306.30

• References & Citations :

  [1]Padmakar Darne C, et al. The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer. Bioorg Med Chem Lett. 2022 Nov 1;75:128951.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported